{
    "id": "257f4dde-e361-4a8d-8821-544eb69f99e7",
    "result_metadata": {
        "score": 1
    },
    "copyright": "",
    "geoOrigin": "",
    "sourceType": "",
    "source": "",
    "corpus_document_id": "75726713973528413254",
    "description": "Kura Oncology Inc\u2013 Equities research analysts at Oppenheimer boosted their FY2022 earnings per share estimates for Kura Oncology in a research report issued to clients and investors on Sunday, May 31st. Oppenheimer analyst J. Olson now forecasts that the company will post earnin",
    "serviceName": "News Service",
    "locationCode": [],
    "sourceClass": "",
    "subjectCode": [
        {
            "parent": null,
            "relevance_score": "9",
            "description": "Business and Commerce",
            "code": "IS/biz#9#99#50",
            "level": 0
        },
        {
            "parent": null,
            "relevance_score": "9",
            "description": "Finance",
            "code": "IS/fin#9#50#99",
            "level": 0
        },
        {
            "parent": "IS/fin",
            "relevance_score": "9",
            "description": "Business Finance and Financing",
            "code": "IS/fin.biz#9#50#99",
            "level": 1
        },
        {
            "parent": "IS/impact",
            "relevance_score": "9",
            "description": "Corporate Earnings",
            "code": "IS/fin.reports#9#99#50",
            "level": 1
        }
    ],
    "text": "Kura Oncology Inc (NASDAQ:KURA) - Equities research analysts at Oppenheimer\nboosted their FY2022 earnings per share (EPS) estimates for Kura Oncology in a\nresearch report issued to clients and investors on Sunday, May 31st.\nOppenheimer analyst J. Olson now forecasts that the company will post earnings\nper share of ($1.66) for the year, up from their previous forecast of ($1.74).\nOppenheimer currently has a \"Buy\" rating and a $27.00 target price on the\nstock. Oppenheimer also issued estimates for Kura Oncology's FY2023 earnings\nat ($0.80) EPS and FY2024 earnings at $0.58 EPS.GetSeveral other analysts have\nalso recently weighed in on KURA. Deutsche Bank decreased their price\nobjective on shares of Kura Oncology from $28.00 to $24.00 and set a \"buy\"\nrating on the stock in a research note on Tuesday, May 19th.Zacks Investment\nResearchShares ofKura Oncology stockKura Oncology (NASDAQ:KURA) last issued\nits quarterly earnings data on Monday, May 4th. The company reported ($0.42)\nearnings per share for the quarter, hitting the Thomson Reuters' consensus\nestimate of ($0.42).Hedge funds and other institutional investors have\nrecently made changes to their positions in the stock. Group One Trading L.P.\nacquired a new position in Kura Oncology in the fourth quarter valued at\napproximately $35,000. FDx Advisors Inc. acquired a new position in Kura\nOncology in the first quarter valued at approximately $37,000. KBC Group NV\nlifted its holdings in Kura Oncology by 104.2% in the fourth quarter. KBC\nGroup NV now owns 4,850 shares of the company's stock valued at $67,000 after\nbuying an additional 2,475 shares during the period. Bank of Montreal Can\nlifted its holdings in Kura Oncology by 60.7% in the fourth quarter. Bank of\nMontreal Can now owns 4,838 shares of the company's stock valued at $67,000\nafter buying an additional 1,828 shares during the period. Finally, Acadian\nAsset Management LLC lifted its holdings in Kura Oncology by 355.7% in the\nfirst quarter. Acadian Asset Management LLC now owns 7,693 shares of the\ncompany's stock valued at $77,000 after buying an additional 6,005 shares\nduring the period. Institutional investors and hedge funds own 87.35% of the\ncompany's stock.About Kura OncologyKura Oncology, Inc, a clinical-stage\nbiopharmaceutical company, develops medicines for the treatment of cancer. Its\npipeline consists of small molecule product candidates that target cancer. The\ncompany's lead product candidate is Tipifarnib, an oral farnesyl transferase\ninhibitor that is in Phase II clinical trials for the treatment of solid\ntumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid\nleukemia, and chronic myelomonocytic leukemia.Recommended Story:What are some\nreasons analysts would give stocks a buy rating?Receive News & Ratings for\nKura Oncology [DailyMarketBeat.com](http://DailyMarketBeat.com)'s FREE daily\nemail newsletter",
    "industryCode": [
        {
            "parent": null,
            "relevance_score": "6",
            "description": "Financial Services and Banking",
            "code": "II/finserv#6#50#65",
            "level": 0
        },
        {
            "parent": "II/finserv",
            "relevance_score": "6",
            "description": "Investing and Brokerage Services",
            "code": "II/finserv.broker#6#50#65",
            "level": 1
        },
        {
            "parent": "II/finserv.broker",
            "relevance_score": "6",
            "description": "Brokerage Services",
            "code": "II/finserv.invest#6#50#65",
            "level": 2
        },
        {
            "parent": "II/finserv.invest",
            "relevance_score": "6",
            "description": "Stock Brokerage",
            "code": "II/finserv.stocks#6#65#50",
            "level": 3
        }
    ],
    "naviga_enrichment": {
        "org": [
            "Kura Oncology Inc",
            "Kura Oncology",
            "Group One Trading L.P.",
            "FDx Advisors Inc.",
            "KBC Group NV",
            "Bank of Montreal Can",
            "Acadian Asset Management LLC",
            "Kura OncologyKura Oncology, Inc",
            "Receive News &amp; Ratings"
        ],
        "location": [],
        "person": [
            "J. Olson"
        ],
        "companies": [
            "Kura Oncology Inc",
            "Group One Trading L.P.",
            "FDx Advisors Inc.",
            "KBC Group NV",
            "Bank of Montreal Can",
            "Kura OncologyKura Oncology, Inc",
            "Acadian Asset Management LLC",
            "Receive News &amp; Ratings",
            "Kura Oncology"
        ]
    },
    "geoOrigin_code": "",
    "language": "en",
    "filename": "202006050426AMSPIDERNEWSSERV_ZOLMAX01_1E5FCDF70E6D6A1EC67FC3B9BAB50EA6_76.XML",
    "providerName": "Acquire Media Spider",
    "enriched_text": {
        "entities": [
            {
                "count": 8,
                "sentiment": {
                    "score": 0.619758,
                    "label": "positive"
                },
                "text": "Kura Oncology",
                "relevance": 0.920746,
                "type": "Facility"
            },
            {
                "count": 4,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Kura",
                "relevance": 0.421122,
                "type": "Location",
                "disambiguation": {
                    "subtype": [
                        "City"
                    ],
                    "name": "Kura, Nigeria",
                    "dbpedia_resource": "http://dbpedia.org/resource/Kura,_Nigeria"
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Kura Oncology Inc",
                "relevance": 0.374291,
                "type": "Company"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Kura OncologyKura Oncology",
                "relevance": 0.311914,
                "type": "Facility"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Oncology stockKura Oncology",
                "relevance": 0.291152,
                "type": "JobTitle"
            },
            {
                "count": 3,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Oppenheimer",
                "relevance": 0.174713,
                "type": "Company"
            },
            {
                "count": 3,
                "sentiment": {
                    "score": -0.568059,
                    "label": "negative"
                },
                "text": "Deutsche Bank",
                "relevance": 0.150293,
                "type": "Company"
            },
            {
                "count": 2,
                "sentiment": {
                    "score": 0.437328,
                    "label": "positive"
                },
                "text": "KBC",
                "relevance": 0.136925,
                "type": "Company",
                "disambiguation": {
                    "subtype": [],
                    "name": "KBC Bank",
                    "dbpedia_resource": "http://dbpedia.org/resource/KBC_Bank"
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Acadian Asset Management LLC",
                "relevance": 0.122216,
                "type": "Company",
                "disambiguation": {
                    "subtype": [],
                    "name": "Acadian Asset Management",
                    "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"
                }
            },
            {
                "count": 2,
                "sentiment": {
                    "score": 0.560916,
                    "label": "positive"
                },
                "text": "Montreal",
                "relevance": 0.118272,
                "type": "Location",
                "disambiguation": {
                    "subtype": [
                        "FictionalUniverse",
                        "GeographicFeature",
                        "AdministrativeDivision",
                        "GovernmentalJurisdiction",
                        "Island",
                        "OlympicHostCity",
                        "City"
                    ],
                    "name": "Montreal",
                    "dbpedia_resource": "http://dbpedia.org/resource/Montreal"
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Thomson Reuters",
                "relevance": 0.101368,
                "type": "PrintMedia"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "analyst",
                "relevance": 0.100206,
                "type": "JobTitle"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0.519175,
                    "label": "positive"
                },
                "text": "NV",
                "relevance": 0.097114,
                "type": "Location",
                "disambiguation": {
                    "subtype": [
                        "StateOrCounty"
                    ]
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "J. Olson",
                "relevance": 0.096997,
                "type": "Person"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Asset Management LLC",
                "relevance": 0.095142,
                "type": "Company"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "FDx Advisors Inc.",
                "relevance": 0.090904,
                "type": "Company"
            },
            {
                "count": 2,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "Tipifarnib",
                "relevance": 0.090616,
                "type": "Drug"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "solidtumors",
                "relevance": 0.090056,
                "type": "HealthCondition",
                "disambiguation": {
                    "subtype": [
                        "DiseaseCause",
                        "RiskFactor",
                        "Symptom"
                    ],
                    "name": "Tumor",
                    "dbpedia_resource": "http://dbpedia.org/resource/Tumor"
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": -0.4098,
                    "label": "negative"
                },
                "text": "leukemia",
                "relevance": 0.088435,
                "type": "HealthCondition"
            },
            {
                "count": 2,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$67,000",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 2,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$0.42",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$35,000",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$37,000",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$77,000",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$24.00",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$27.00",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$28.00",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "104.2%",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "355.7%",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "87.35%",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$0.58",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$0.80",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$1.66",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$1.74",
                "relevance": 0.088435,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "60.7%",
                "relevance": 0.088435,
                "type": "Quantity"
            }
        ],
        "semantic_roles": [
            {
                "subject": {
                    "text": "research report"
                },
                "sentence": " research report issued to clients and investors on Sunday, May 31st.",
                "object": {
                    "text": "to clients"
                },
                "action": {
                    "verb": {
                        "text": "issue",
                        "tense": "past"
                    },
                    "text": "issued",
                    "normalized": "issue"
                }
            },
            {
                "subject": {
                    "text": "Oppenheimer analyst J. Olson"
                },
                "sentence": " Oppenheimer analyst J. Olson now forecasts that the company will post earnings",
                "object": {
                    "text": "that the company will post earnings"
                },
                "action": {
                    "verb": {
                        "text": "forecast",
                        "tense": "present"
                    },
                    "text": "forecasts",
                    "normalized": "forecast"
                }
            },
            {
                "subject": {
                    "text": "Oppenheimer"
                },
                "sentence": " Oppenheimer currently has a \"Buy\" rating and a $27.00 target price on the",
                "object": {
                    "text": "a \"Buy\" rating and a $27.00 target price on the"
                },
                "action": {
                    "verb": {
                        "text": "have",
                        "tense": "present"
                    },
                    "text": "has",
                    "normalized": "have"
                }
            },
            {
                "subject": {
                    "text": "stock. Oppenheimer"
                },
                "sentence": " stock. Oppenheimer also issued estimates for Kura Oncology's FY2023 earnings",
                "object": {
                    "text": "estimates for Kura Oncology's FY2023 earnings"
                },
                "action": {
                    "verb": {
                        "text": "issue",
                        "tense": "past"
                    },
                    "text": "issued",
                    "normalized": "issue"
                }
            },
            {
                "subject": {
                    "text": "on KURA"
                },
                "sentence": " also recently weighed in on KURA.",
                "action": {
                    "verb": {
                        "text": "weigh",
                        "tense": "past"
                    },
                    "text": "weighed",
                    "normalized": "weigh"
                }
            },
            {
                "subject": {
                    "text": "Deutsche Bank"
                },
                "sentence": " Deutsche Bank decreased their price",
                "object": {
                    "text": "their price"
                },
                "action": {
                    "verb": {
                        "text": "decrease",
                        "tense": "past"
                    },
                    "text": "decreased",
                    "normalized": "decrease"
                }
            },
            {
                "subject": {
                    "text": "objective on shares of Kura Oncology"
                },
                "sentence": " objective on shares of Kura Oncology from $28.00 to $24.00 and set a \"buy\"",
                "object": {
                    "text": "a \"buy\""
                },
                "action": {
                    "verb": {
                        "text": "set",
                        "tense": "past"
                    },
                    "text": "set",
                    "normalized": "set"
                }
            },
            {
                "subject": {
                    "text": "KURA)"
                },
                "sentence": " ResearchShares ofKura Oncology stockKura Oncology (NASDAQ:KURA) last issued",
                "action": {
                    "verb": {
                        "text": "issue",
                        "tense": "past"
                    },
                    "text": "issued",
                    "normalized": "issue"
                }
            },
            {
                "subject": {
                    "text": "earnings"
                },
                "sentence": " earnings per share for the quarter, hitting the Thomson Reuters' consensus",
                "object": {
                    "text": "the Thomson Reuters' consensus"
                },
                "action": {
                    "verb": {
                        "text": "hit",
                        "tense": "present"
                    },
                    "text": "hitting",
                    "normalized": "hit"
                }
            },
            {
                "subject": {
                    "text": "changes"
                },
                "sentence": " recently made changes to their positions in the stock.",
                "object": {
                    "text": "to their positions in the stock"
                },
                "action": {
                    "verb": {
                        "text": "make",
                        "tense": "past"
                    },
                    "text": "made",
                    "normalized": "make"
                }
            },
            {
                "subject": {
                    "text": "a new position in Kura Oncology"
                },
                "sentence": " acquired a new position in Kura Oncology in the fourth quarter valued at",
                "action": {
                    "verb": {
                        "text": "acquire",
                        "tense": "past"
                    },
                    "text": "acquired",
                    "normalized": "acquire"
                }
            },
            {
                "subject": {
                    "text": "FDx Advisors Inc."
                },
                "sentence": " FDx Advisors Inc. acquired a new position in Kura",
                "object": {
                    "text": "a new position in Kura"
                },
                "action": {
                    "verb": {
                        "text": "acquire",
                        "tense": "past"
                    },
                    "text": "acquired",
                    "normalized": "acquire"
                }
            },
            {
                "subject": {
                    "text": "Oncology in the first quarter"
                },
                "sentence": " Oncology in the first quarter valued at approximately $37,000.",
                "object": {
                    "text": "at approximately $37,000"
                },
                "action": {
                    "verb": {
                        "text": "value",
                        "tense": "past"
                    },
                    "text": "valued",
                    "normalized": "value"
                }
            },
            {
                "subject": {
                    "text": "its holdings in Kura Oncology"
                },
                "sentence": " lifted its holdings in Kura Oncology by 104.2% in the fourth quarter.",
                "object": {
                    "text": "by 104.2%"
                },
                "action": {
                    "verb": {
                        "text": "lift",
                        "tense": "past"
                    },
                    "text": "lifted",
                    "normalized": "lift"
                }
            },
            {
                "subject": {
                    "text": "Group NV"
                },
                "sentence": " Group NV now owns 4,850 shares of the company's stock valued at $67,000 after",
                "object": {
                    "text": "4,850 shares of the company's stock valued at $67,000"
                },
                "action": {
                    "verb": {
                        "text": "own",
                        "tense": "present"
                    },
                    "text": "owns",
                    "normalized": "own"
                }
            },
            {
                "subject": {
                    "text": "the company's stock"
                },
                "sentence": " Group NV now owns 4,850 shares of the company's stock valued at $67,000 after",
                "object": {
                    "text": "at $67,000 after"
                },
                "action": {
                    "verb": {
                        "text": "value",
                        "tense": "past"
                    },
                    "text": "valued",
                    "normalized": "value"
                }
            },
            {
                "subject": {
                    "text": "an additional 2,475 shares"
                },
                "sentence": " buying an additional 2,475 shares during the period.",
                "action": {
                    "verb": {
                        "text": "buy",
                        "tense": "present"
                    },
                    "text": "buying",
                    "normalized": "buy"
                }
            },
            {
                "subject": {
                    "text": "its holdings in Kura Oncology"
                },
                "sentence": " lifted its holdings in Kura Oncology by 60.7% in the fourth quarter.",
                "object": {
                    "text": "by 60.7%"
                },
                "action": {
                    "verb": {
                        "text": "lift",
                        "tense": "past"
                    },
                    "text": "lifted",
                    "normalized": "lift"
                }
            },
            {
                "subject": {
                    "text": "Montreal"
                },
                "sentence": " Montreal Can now owns 4,838 shares of the company's stock valued at $67,000",
                "object": {
                    "text": "4,838 shares of the company's stock valued at $67,000"
                },
                "action": {
                    "verb": {
                        "text": "own",
                        "tense": "future"
                    },
                    "text": "owns",
                    "normalized": "own"
                }
            },
            {
                "subject": {
                    "text": "an additional 1,828 shares"
                },
                "sentence": " after buying an additional 1,828 shares during the period.",
                "action": {
                    "verb": {
                        "text": "buy",
                        "tense": "present"
                    },
                    "text": "buying",
                    "normalized": "buy"
                }
            },
            {
                "subject": {
                    "text": "Asset Management LLC"
                },
                "sentence": " Asset Management LLC lifted its holdings in Kura Oncology by 355.7% in the",
                "object": {
                    "text": "its holdings in Kura Oncology"
                },
                "action": {
                    "verb": {
                        "text": "lift",
                        "tense": "past"
                    },
                    "text": "lifted",
                    "normalized": "lift"
                }
            },
            {
                "subject": {
                    "text": "Acadian Asset Management LLC"
                },
                "sentence": " Acadian Asset Management LLC now owns 7,693 shares of the",
                "object": {
                    "text": "7,693 shares of the"
                },
                "action": {
                    "verb": {
                        "text": "own",
                        "tense": "present"
                    },
                    "text": "owns",
                    "normalized": "own"
                }
            },
            {
                "subject": {
                    "text": "company's stock"
                },
                "sentence": " company's stock valued at $77,000 after buying an additional 6,005 shares",
                "object": {
                    "text": "at $77,000"
                },
                "action": {
                    "verb": {
                        "text": "value",
                        "tense": "past"
                    },
                    "text": "valued",
                    "normalized": "value"
                }
            },
            {
                "subject": {
                    "text": "company"
                },
                "sentence": " company's stock valued at $77,000 after buying an additional 6,005 shares",
                "object": {
                    "text": "an additional 6,005 shares"
                },
                "action": {
                    "verb": {
                        "text": "buy",
                        "tense": "present"
                    },
                    "text": "buying",
                    "normalized": "buy"
                }
            },
            {
                "subject": {
                    "text": "funds"
                },
                "sentence": " Institutional investors and hedge funds own 87.35% of the",
                "object": {
                    "text": "own 87.35% of the"
                },
                "action": {
                    "verb": {
                        "text": "hedge",
                        "tense": "present"
                    },
                    "text": "hedge",
                    "normalized": "hedge"
                }
            },
            {
                "subject": {
                    "text": "pipeline"
                },
                "sentence": " pipeline consists of small molecule product candidates that target cancer.",
                "object": {
                    "text": "of small molecule product candidates that target cancer"
                },
                "action": {
                    "verb": {
                        "text": "consist",
                        "tense": "present"
                    },
                    "text": "consists",
                    "normalized": "consist"
                }
            },
            {
                "subject": {
                    "text": "small molecule product candidates"
                },
                "sentence": " pipeline consists of small molecule product candidates that target cancer.",
                "object": {
                    "text": "cancer"
                },
                "action": {
                    "verb": {
                        "text": "target",
                        "tense": "present"
                    },
                    "text": "target",
                    "normalized": "target"
                }
            },
            {
                "subject": {
                    "text": "company's lead product candidate"
                },
                "sentence": " company's lead product candidate is Tipifarnib, an oral farnesyl transferase",
                "object": {
                    "text": "Tipifarnib"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "inhibitor"
                },
                "sentence": " inhibitor that is in Phase II clinical trials for the treatment of solid",
                "object": {
                    "text": "in Phase II clinical trials for the treatment of solid"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "analysts"
                },
                "sentence": " reasons analysts would give stocks a buy rating?Receive News & Ratings for",
                "object": {
                    "text": "a buy rating"
                },
                "action": {
                    "verb": {
                        "text": "give",
                        "tense": "future"
                    },
                    "text": "would give",
                    "normalized": "would give"
                }
            },
            {
                "subject": {
                    "text": "analysts"
                },
                "sentence": " reasons analysts would give stocks a buy rating?Receive News & Ratings for",
                "object": {
                    "text": "News & Ratings"
                },
                "action": {
                    "verb": {
                        "text": "Receive",
                        "tense": "present"
                    },
                    "text": "Receive",
                    "normalized": "Receive"
                }
            },
            {
                "subject": {
                    "text": "Kura Oncology [DailyMarketBeat.com](http://DailyMarketBeat.com)'s"
                },
                "sentence": " Kura Oncology [DailyMarketBeat.com](http://DailyMarketBeat.com)'s FREE daily",
                "action": {
                    "verb": {
                        "text": "FREE",
                        "tense": "present"
                    },
                    "text": "FREE",
                    "normalized": "FREE"
                }
            }
        ],
        "categories": [
            {
                "score": 0.850223,
                "label": "/health and fitness/disease/cancer"
            },
            {
                "score": 0.831904,
                "label": "/finance/investing"
            },
            {
                "score": 0.831904,
                "label": "/finance/investing/beginning investing"
            }
        ],
        "relations": [
            {
                "type": "partOf",
                "sentence": "Kura Oncology Inc (NASDAQ:KURA) - Equities research analysts at Oppenheimer boosted their FY2022 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Sunday, May 31st.",
                "score": 0.40482,
                "arguments": [
                    {
                        "text": "Kura Oncology Inc",
                        "location": [
                            0,
                            17
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology Inc"
                            }
                        ]
                    },
                    {
                        "text": "Oppenheimer",
                        "location": [
                            64,
                            75
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Oppenheimer",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "affectedBy",
                "sentence": "Group One Trading L.P. acquired a new position in Kura Oncology in the fourth quarter valued at approximately $35,000.",
                "score": 0.533278,
                "arguments": [
                    {
                        "text": "Kura Oncology",
                        "location": [
                            1238,
                            1251
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "text": "acquired",
                        "location": [
                            1211,
                            1219
                        ],
                        "entities": [
                            {
                                "type": "EventBusiness",
                                "text": "acquired"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "agentOf",
                "sentence": "FDx Advisors Inc. acquired a new position in Kura Oncology in the first quarter valued at approximately $37,000.",
                "score": 0.908776,
                "arguments": [
                    {
                        "text": "FDx Advisors Inc.",
                        "location": [
                            1307,
                            1324
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "FDx Advisors Inc.",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "text": "acquired",
                        "location": [
                            1325,
                            1333
                        ],
                        "entities": [
                            {
                                "type": "EventBusiness",
                                "text": "acquired"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "affectedBy",
                "sentence": "FDx Advisors Inc. acquired a new position in Kura Oncology in the first quarter valued at approximately $37,000.",
                "score": 0.533278,
                "arguments": [
                    {
                        "text": "Kura\nOncology",
                        "location": [
                            1352,
                            1365
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura\nOncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "text": "acquired",
                        "location": [
                            1325,
                            1333
                        ],
                        "entities": [
                            {
                                "type": "EventBusiness",
                                "text": "acquired"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "partOf",
                "sentence": "KBC Group NV lifted its holdings in Kura Oncology by 104.2% in the fourth quarter.",
                "score": 0.589501,
                "arguments": [
                    {
                        "text": "its",
                        "location": [
                            1440,
                            1443
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Group One Trading L.P."
                            }
                        ]
                    },
                    {
                        "text": "Kura Oncology",
                        "location": [
                            1456,
                            1469
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "partOf",
                "sentence": "Bank of Montreal Can lifted its holdings in Kura Oncology by 60.7% in the fourth quarter.",
                "score": 0.589501,
                "arguments": [
                    {
                        "text": "its",
                        "location": [
                            1666,
                            1669
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Group One Trading L.P."
                            }
                        ]
                    },
                    {
                        "text": "Kura Oncology",
                        "location": [
                            1682,
                            1695
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "partOf",
                "sentence": "Finally, Acadian Asset Management LLC lifted its holdings in Kura Oncology by 355.7% in the first quarter.",
                "score": 0.589501,
                "arguments": [
                    {
                        "text": "its",
                        "location": [
                            1916,
                            1919
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Group One Trading L.P."
                            }
                        ]
                    },
                    {
                        "text": "Kura Oncology",
                        "location": [
                            1932,
                            1945
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "hasAttribute",
                "sentence": "Its pipeline consists of small molecule product candidates that target cancer.",
                "score": 0.870896,
                "arguments": [
                    {
                        "text": "candidates",
                        "location": [
                            2382,
                            2392
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "candidates"
                            }
                        ]
                    },
                    {
                        "text": "cancer",
                        "location": [
                            2405,
                            2411
                        ],
                        "entities": [
                            {
                                "type": "HealthCondition",
                                "text": "leukemia"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "employedBy",
                "sentence": "Kura Oncology Inc (NASDAQ:KURA) - Equities research analysts at Oppenheimer boosted their FY2022 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Sunday, May 31st.",
                "score": 0.670465,
                "arguments": [
                    {
                        "text": "analysts",
                        "location": [
                            52,
                            60
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "analysts"
                            }
                        ]
                    },
                    {
                        "text": "Oppenheimer",
                        "location": [
                            64,
                            75
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Oppenheimer",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "employedBy",
                "sentence": "Oppenheimer analyst J. Olson now forecasts that the company will post earnings per share of ($1.66) for the year, up from their previous forecast of ($1.74).",
                "score": 0.641939,
                "arguments": [
                    {
                        "text": "analyst",
                        "location": [
                            236,
                            243
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "J. Olson"
                            }
                        ]
                    },
                    {
                        "text": "Oppenheimer",
                        "location": [
                            224,
                            235
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Oppenheimer",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "partOf",
                "sentence": "Oppenheimer also issued estimates for Kura Oncology's FY2023 earnings at ($0.80) EPS and FY2024 earnings at $0.58 EPS.GetSeveral other analysts have also recently weighed in on KURA.",
                "score": 0.533267,
                "arguments": [
                    {
                        "text": "FY2023",
                        "location": [
                            517,
                            523
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "FY2023",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "text": "Kura Oncology",
                        "location": [
                            501,
                            514
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "employedBy",
                "sentence": "Oppenheimer also issued estimates for Kura Oncology's FY2023 earnings at ($0.80) EPS and FY2024 earnings at $0.58 EPS.GetSeveral other analysts have also recently weighed in on KURA.",
                "score": 0.433794,
                "arguments": [
                    {
                        "text": "analysts",
                        "location": [
                            598,
                            606
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "analysts"
                            }
                        ]
                    },
                    {
                        "text": "FY2024",
                        "location": [
                            552,
                            558
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "FY2024",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "locatedAt",
                "sentence": "Oppenheimer also issued estimates for Kura Oncology's FY2023 earnings at ($0.80) EPS and FY2024 earnings at $0.58 EPS.GetSeveral other analysts have also recently weighed in on KURA.",
                "score": 0.728899,
                "arguments": [
                    {
                        "text": "analysts",
                        "location": [
                            598,
                            606
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "analysts"
                            }
                        ]
                    },
                    {
                        "text": "KURA",
                        "location": [
                            640,
                            644
                        ],
                        "entities": [
                            {
                                "type": "GeopoliticalEntity",
                                "text": "KURA"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "employedBy",
                "sentence": "Deutsche Bank decreased their price objective on shares of Kura Oncology from $28.00 to $24.00 and set a \"buy\" rating on the stock in a research note on Tuesday, May 19th.Zacks Investment ResearchShares ofKura Oncology stockKura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, May 4th.",
                "score": 0.381198,
                "arguments": [
                    {
                        "text": "their",
                        "location": [
                            670,
                            675
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "investors"
                            }
                        ]
                    },
                    {
                        "text": "Kura Oncology",
                        "location": [
                            705,
                            718
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "agentOf",
                "sentence": "The company reported ($0.42) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.42).",
                "score": 0.993089,
                "arguments": [
                    {
                        "text": "company",
                        "location": [
                            962,
                            969
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Kura Oncology Inc"
                            }
                        ]
                    },
                    {
                        "text": "reported",
                        "location": [
                            970,
                            978
                        ],
                        "entities": [
                            {
                                "type": "EventCommunication",
                                "text": "reported"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "agentOf",
                "sentence": "Group One Trading L.P. acquired a new position in Kura Oncology in the fourth quarter valued at approximately $35,000.",
                "score": 0.918576,
                "arguments": [
                    {
                        "text": "Group One Trading L.P.",
                        "location": [
                            1188,
                            1210
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "Group One Trading L.P."
                            }
                        ]
                    },
                    {
                        "text": "acquired",
                        "location": [
                            1211,
                            1219
                        ],
                        "entities": [
                            {
                                "type": "EventBusiness",
                                "text": "acquired"
                            }
                        ]
                    }
                ]
            }
        ],
        "keywords": [
            {
                "text": "Kura Oncology Inc",
                "relevance": 0.782719,
                "count": 1
            },
            {
                "text": "Acadian Asset Management LLC",
                "relevance": 0.701703,
                "count": 1
            },
            {
                "text": "Equities research analysts",
                "relevance": 0.64289,
                "count": 1
            },
            {
                "text": "Deutsche Bank",
                "relevance": 0.628214,
                "count": 1
            },
            {
                "text": "FY2022 earnings",
                "relevance": 0.622067,
                "count": 1
            },
            {
                "text": "KBC Group NV",
                "relevance": 0.615703,
                "count": 1
            },
            {
                "text": "FDx Advisors Inc.",
                "relevance": 0.59932,
                "count": 1
            },
            {
                "text": "Kura Oncology",
                "relevance": 0.596965,
                "count": 6
            },
            {
                "text": "Hedge funds",
                "relevance": 0.588868,
                "count": 2
            },
            {
                "text": "research report",
                "relevance": 0.577492,
                "count": 1
            },
            {
                "text": "institutional investors",
                "relevance": 0.575541,
                "count": 2
            },
            {
                "text": "Kura Oncology's FY2023 earnings",
                "relevance": 0.574671,
                "count": 1
            },
            {
                "text": "Oppenheimer analyst J. Olson",
                "relevance": 0.570864,
                "count": 1
            },
            {
                "text": "shares of Kura Oncology",
                "relevance": 0.549667,
                "count": 1
            },
            {
                "text": "company",
                "relevance": 0.545925,
                "count": 2
            },
            {
                "text": "peripheral T-cell lymphomas",
                "relevance": 0.543938,
                "count": 1
            },
            {
                "text": "share",
                "relevance": 0.541098,
                "count": 3
            },
            {
                "text": "clinical trials",
                "relevance": 0.539909,
                "count": 1
            },
            {
                "text": "myelodysplastic syndromes",
                "relevance": 0.538883,
                "count": 1
            },
            {
                "text": "shares of the company",
                "relevance": 0.535178,
                "count": 2
            },
            {
                "text": "fourth quarter",
                "relevance": 0.533014,
                "count": 3
            },
            {
                "text": "Thomson Reuters",
                "relevance": 0.532089,
                "count": 1
            },
            {
                "text": "company's stock.About Kura OncologyKura Oncology",
                "relevance": 0.532062,
                "count": 1
            },
            {
                "text": "small molecule product candidates",
                "relevance": 0.528356,
                "count": 1
            },
            {
                "text": "KURA",
                "relevance": 0.527701,
                "count": 3
            },
            {
                "text": "Oppenheimer",
                "relevance": 0.525381,
                "count": 3
            },
            {
                "text": "Bank of Montreal Can",
                "relevance": 0.523916,
                "count": 1
            },
            {
                "text": "estimates",
                "relevance": 0.523502,
                "count": 2
            },
            {
                "text": "stock",
                "relevance": 0.519711,
                "count": 5
            },
            {
                "text": "pipeline",
                "relevance": 0.519157,
                "count": 1
            },
            {
                "text": "NASDAQ",
                "relevance": 0.518201,
                "count": 2
            },
            {
                "text": "earnings",
                "relevance": 0.513803,
                "count": 2
            },
            {
                "text": "investors",
                "relevance": 0.513309,
                "count": 1
            },
            {
                "text": "reasons analysts",
                "relevance": 0.512469,
                "count": 1
            },
            {
                "text": "holdings",
                "relevance": 0.512239,
                "count": 3
            },
            {
                "text": "quarterly earnings data",
                "relevance": 0.509916,
                "count": 1
            },
            {
                "text": "analysts",
                "relevance": 0.509171,
                "count": 1
            },
            {
                "text": "positions",
                "relevance": 0.508984,
                "count": 1
            },
            {
                "text": "quarter",
                "relevance": 0.508523,
                "count": 1
            },
            {
                "text": "company's lead product candidate",
                "relevance": 0.508444,
                "count": 1
            },
            {
                "text": "Inc",
                "relevance": 0.507592,
                "count": 1
            },
            {
                "text": "shares",
                "relevance": 0.506865,
                "count": 4
            },
            {
                "text": "Phase",
                "relevance": 0.506784,
                "count": 1
            },
            {
                "text": "clients",
                "relevance": 0.506764,
                "count": 1
            },
            {
                "text": "rating",
                "relevance": 0.506551,
                "count": 1
            },
            {
                "text": "year",
                "relevance": 0.506456,
                "count": 1
            },
            {
                "text": "Montreal",
                "relevance": 0.506033,
                "count": 1
            },
            {
                "text": "Bank",
                "relevance": 0.505693,
                "count": 1
            },
            {
                "text": "changes",
                "relevance": 0.505375,
                "count": 1
            },
            {
                "text": "medicines",
                "relevance": 0.504203,
                "count": 1
            }
        ]
    },
    "freqeuncy": "",
    "extracted_metadata": {
        "sha1": "cd328abf60babfc167db8995bd243cec89fe9171",
        "filename": "202006050426AMSPIDERNEWSSERV_ZOLMAX01_1E5FCDF70E6D6A1EC67FC3B9BAB50EA6_76.json",
        "file_type": "json"
    },
    "companyRecord": "|||Acadian Asset Management LLC|extractor|DUNS:832096767;NECOID:184881128;ACORN:0173881128;UDUNS:235938714;UACORN:3427249042|MENTION||||XXXX|REFERENCE",
    "publicationTime": "2020-06-05T04:26:00-04:00",
    "title": "Brokers Issue Forecasts for Kura Oncology Inc\u2019s FY2022 Earnings (NASDAQ:KURA) [Zolmax News]",
    "html": "<p><org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology Inc</org> (NASDAQ:KURA) &#8211; Equities research analysts at  Oppenheimer boosted their FY2022 earnings per share (EPS) estimates for <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org>  in a research report issued to clients and investors on  <chron>Sunday, May 31st</chron>. Oppenheimer analyst <person>J. Olson</person> now forecasts that the company will post earnings per share of (<money>$1.66</money>) for the year, up from their previous forecast of (<money>$1.74</money>). Oppenheimer currently  has a &#8220;Buy&#8221; rating and a <money>$27.00</money> target price on the stock. Oppenheimer also issued estimates for Kura Oncology&#8217;s FY2023 earnings at (<money>$0.80</money>) EPS and FY2024 earnings at <money>$0.58</money> EPS.GetSeveral other analysts have also recently weighed in on KURA. Deutsche Bank decreased their price objective on shares of <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> from <money>$28.00</money> to <money>$24.00</money> and set a &#8220;buy&#8221; rating on the stock in a research note on Tuesday, May 19th.Zacks Investment ResearchShares ofKura Oncology stock<org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> (NASDAQ:KURA) last issued its quarterly earnings data on <chron>Monday, May 4th</chron>. The company reported (<money>$0.42</money>) earnings per share for the quarter, hitting the Thomson Reuters&#8217; consensus estimate of (<money>$0.42</money>).Hedge funds and other institutional investors have recently made changes to their positions in the stock. <org>Group One Trading L.P.</org> acquired a new position in  <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> in the fourth quarter valued at approximately <money>$35,000</money>.  <org>FDx Advisors Inc.</org> acquired a new position in  <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> in the first quarter valued at approximately <money>$37,000</money>.  <org idsrc=\"xmltag.org\" value=\"EuronextBrussels:KBC\">KBC Group NV</org> lifted its holdings in  <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> by 104.2% in the fourth quarter. <org idsrc=\"xmltag.org\" value=\"EuronextBrussels:KBC\">KBC Group NV</org> now owns 4,850 shares of the company&#8217;s stock valued at <money>$67,000</money> after buying an additional 2,475 shares during the period.  <org>Bank of Montreal Can</org> lifted its holdings in  <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> by 60.7% in the fourth quarter. <org>Bank of Montreal Can</org> now owns 4,838 shares of the company&#8217;s stock valued at <money>$67,000</money> after buying an additional 1,828 shares during the period.  Finally, <org idsrc=\"xmltag.org\" value=\"ACORN:0173881128\">Acadian Asset Management LLC</org> lifted its holdings in  <org idsrc=\"xmltag.org\" value=\"NASDAQ-NMS:KURA\">Kura Oncology</org> by 355.7% in the first quarter. <org idsrc=\"xmltag.org\" value=\"ACORN:0173881128\">Acadian Asset Management LLC</org> now owns 7,693 shares of the company&#8217;s stock valued at <money>$77,000</money> after buying an additional 6,005 shares during the period. Institutional investors and hedge funds own  87.35% of the company&#8217;s stock.About <org>Kura OncologyKura Oncology, Inc</org>, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.Recommended Story:What are some reasons analysts would give stocks a buy rating?<org>Receive News &amp; Ratings</org> for Kura Oncology <a href=\"http://DailyMarketBeat.com\">DailyMarketBeat.com</a>'s FREE daily email newsletter</p>",
    "geoFocus": []
}